A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

Conclusion.Nivolumab monotherapy at 3 mg/kg and flat doses of 240 mg and 360 mg were well tolerated in this Chinese patient population, with PK profiles at 3 mg/kg being similar to those of global patients. Preliminary efficacy results showed promising antitumor activity of nivolumab in advanced NPC.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Yuxiang Ma, Wenfeng Fang, Yang Zhang, Yunpeng Yang, Shaodong Hong, Yuanyuan Zhao, Amol Tendolkar, Lu Chen, Dong Xu, Jennifer Sheng, Hongyun Zhao, Li Zhang Tags: Chinese Edition, Clinical Trial Results Source Type: research